Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 1/2008

01.02.2008

Effects of Hawthorn on Cardiac Remodeling and Left Ventricular Dysfunction after 1 Month of Pressure Overload-induced Cardiac Hypertrophy in Rats

verfasst von: Hyun Seok Hwang, Barry E. Bleske, Michael M. J. Ghannam, Kimber Converso, Mark W. Russell, James C. Hunter, Marvin O. Boluyt

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hawthorn (Crataegus) is a natural product used to treat patients with heart failure. The effects of hawthorn on cardiac remodeling, however, are not known. The purpose was to determine the effects of hawthorn treatment on remodeling and function of the left ventricle (LV) after 1 month of pressure overload-induced cardiac hypertrophy.

Materials and methods

Sprague-Dawley rats (male, 300 g) were subjected to sham operation (SH) or aortic constriction (AC) for 4 weeks and treated with Hawthorn (Crataegus-Extract- WS1442;1.3, 13, 130 mg kg−1 day−1; AC-L, AC-M, AC-H) or vehicle (SH-V, AC-V) for 3 weeks after surgery. Systolic and diastolic function were measured using echocardiographic assessment at baseline and 4 weeks after AC.

Results

AC increased the LV/body weight ratio by 34% in vehicle and hawthorn treated rats. Hawthorn markedly reduced LV chamber volumes (VOL) after AC [systolic VOL, mean ± SEM, mm3: SH-V, 87 ± 13; AC-V, 93 ± 12; AC-L, 62 ± 9; AC-M, 68 ± 12; AC-H; 50 ± 11 and diastolic VOL: SH-V, 433 ± 45; AC-V, 412 ± 57; AC-L, 313 ± 25; AC-M, 319 ± 37; AC-H, 264 ± 25 (p < 0.05)] and augmented relative wall thickness, mm: SH-V, 0.45 ± 0.02; AC-V, 0.65 ± 0.05; AC-L, 0.71 ± 0.03; AC-M, 0.74 ± 0.06; AC-H, 0.80 ± 0.09 (p < 0.05). AC reduced velocity of circumferential shortening (Vcfc) by 28% compared with SH-V. Hawthorn attenuated the AC-induced decrease in Vcfc (p < 0.05).

Conclusions

Hawthorn treatment modifies left ventricular remodeling and counteracts myocardial dysfunction in early pressure overload-induced cardiac hypertrophy.
Literatur
1.
Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45–79.PubMedCrossRef
2.
Popping S, Rose H, Ionescu I, Fischer Y, Kammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995;45:1157–61.PubMed
3.
Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995;45:842–5.PubMed
4.
Chang Q, Zhu M, Zuo Z, Chow M, Ho WK. High-performance liquid chromatographic method for simultaneous determination of hawthorn active components in rat plasma. J Chromatogr B Biomed Sci Appl 2001;42:605–12.
5.
Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003;114:665–74.PubMedCrossRef
6.
Rietbrock N, Hamel M, Hempel B, Mitrovic V, Schmidt T, Wolf GK. Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure. Arzneimittel-Forschung 2001;51:793–8.PubMed
7.
Tauchert M, Gildor A, Lipinski J. High dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure. Herz 1999;24:465–74.PubMed
8.
Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002;143:910–5.PubMedCrossRef
9.
Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004;74:1945–55.PubMedCrossRef
10.
Boluyt MO, Opiteck JA, Devor ST, White TP. Age effects on the adaptive response of the female rat heart following aortic constriction. J Gerontol A Biol Sci Med Sci 2000;55A:B307–314.
11.
Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, Jackson RR. The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther 2004a;18:257–67.PubMedCrossRef
12.
Boluyt MO, Converso K, Hwang HS, Mikkor A, Russell MW. Echocardiographic assessment of age-associated changes in systolic and diastolic function of the female F344 rat heart. J Appl Physiol 2004b;96:822–8.PubMedCrossRef
13.
Boluyt MO, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: Marked upregulation of genes encoding extracellular matrix proteins. Circ Res 1994;75:23–32.PubMed
14.
Boluyt MO, Brevick JL, Rogers DS, Randall MJ, Scalia AF, Li ZB. Changes in the rat heart proteome induced by exercise training: Increased abundance of heat shock protein hsp20. Proteomics 2006;10:3154–69.CrossRef
15.
Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984–91.PubMedCrossRef
16.
Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Current Heart Failure Reports 2007;4:18–25.PubMed
17.
Zhang M, Shah AM. Role of reactive oxygen species in myocardial remodeling. Current Heart Failure Reports 2007;4:26–30.PubMedCrossRef
18.
Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527–37.PubMedCrossRef
19.
Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure. Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006;48:A56–66.CrossRef
20.
Bahorun T, Trotin F, Pommery J, Vasseur J, Pinkas M. Antioxidant activities of Crataegus monogyna extracts. Planta Med 1994;60:323–8.PubMedCrossRef
21.
Bahourn T, Aumjaud E, Ramphul H, et al. Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts. Food 2003;47:191–8.
22.
Chu CY, Lee MJ, Liao CL, Lin WL, Yin YF, Tseng TH. Inhibitory effect of hot-water extract from dried fruit of Crataegus pinnatifida on low-density lipoprotein (LDL) oxidation in cell and cell-free systems. J Agric Food Chem 2003;51:7583–8.PubMedCrossRef
23.
Zhang Z, Chang Q, Zhu M, Huang Y, Ho WKK, Chen ZY. Characterization of antioxidants present in hawthorn fruits. J Nutr Biochem 2001;12:144–52.PubMedCrossRef
24.
Jayalakshmi R, Niranjali DS. Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats. J Pharm Pharmacol 2004;56:921–6.PubMedCrossRef
25.
Shanthi R, Parasakthy K, Deepalakshmi PD, Niranjali DS. Protective effect of tincture of Crataegus on oxidative stress in experimental atherosclerosis in rats. J Clin Biochem Nutr 1996;20:211–23.
26.
Aucamp J, Gaspar A, Hara Y, Apostolides Z. Inhibition of xanthine oxidase by catechins from tea (Carmellia sinensis). Anticancer Res 1997;17:4381–5.PubMed
27.
Huang SM, Wu CH, Yen GC. Effects of flavonoids on the expression of the pro-inflammatory response in human monocytes induced by ligation of the receptor for AGEs. Mol Nutr Food Res 2006;50:1129–39.PubMedCrossRef
28.
Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ. Distinctive antioxidant and anti-inflammatory effects of flavonols. J Agric Food Chem 2006;54:9798–804.PubMedCrossRef
29.
Sanchez M, Galisteo M, Vera R, et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 2006;24:75–84.PubMedCrossRef
30.
Kim SH, Kang KW, Kim KW, Kim KD. Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sci 2000;67:121–31.PubMedCrossRef
31.
Chen ZY, Zhang ZS, Kwan KY, Zhu M, Ho WK, Huang Y. Endothelium-dependent relaxation induced by hawthorn extract in rat mesenteric artery. Life Sci 1998;63:1983–91.PubMedCrossRef
32.
Steffen Y, Schewe T, Sies H. Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase. Biochem Biophys Res Commun 2005;331:1277–83.PubMedCrossRef
33.
Benito S, Lopez D, Saiz MP, et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br J Pharmacol 2002;135:910–6.PubMedCrossRef
34.
Karim M, McCormick K, Kappagoda CT. Effects of cocoa extracts on endothelium-dependent relaxation. J Nutr 2000;130:2105S–8S.PubMed
35.
Schroeter H, Heiss C, Balzer J, et al. (−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 2006;103:1024–9.PubMedCrossRef
36.
Kao ES, Wang CJ, Lin WL, Yin YF, Wang CP, Tseng TH. Anti-inflammatory potential of flavonoid contents from dried fruit of Crataegus pinnatifida in vitro and in vivo. J Agric Food Chem 2005;53:430–6.PubMedCrossRef
37.
Garcia-Mediavilla V, Crespo I, Collado PS, et al. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang liver cells. Eur J Pharmacol 2007;557:221–9.PubMedCrossRef
38.
Kim MJ, Ryu GR, Kang JH, et al. Inhibitory effects of epicatechin on interleukin-1beta-induced inducible nitric oxide synthase expression in RINm5F cells and rat pancreatic islets by down-regulation of NF-kappaB activation. Biochem Pharmacol 2004;68:1775–85.PubMedCrossRef
39.
Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: Antioxidants or signalling molecules? Free Rad Biomed 2004;36:838–49.CrossRef
40.
Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007;73:348–58.PubMedCrossRef
41.
Oak MH, Chataigneau M, Keravis T, et al. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol 2003;23:1001–7.PubMedCrossRef
42.
Petkov E, Nikolov N, Uzunov P. Inhibitory effect of some flavonoids and flavonoid mixtures on cyclic AMP phosphodiesterase activity of rat heart. Planta Med 1981;43:183–6.CrossRef
43.
Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000;35:700–7.PubMedCrossRef
44.
Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE. 3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol 2006;47:521–30.PubMedCrossRef
45.
McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 200422;109:3050–5.CrossRef
46.
Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992;262:H1861–1866.PubMed
47.
Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987;252:C1–9.PubMed
48.
Eghbali M, Weber KT. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 1990;96:1–14.PubMedCrossRef
49.
Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281–92.PubMedCrossRef
50.
Aaronson K. HERB-CHF (Hawthorn Extract Randomized Blinded Chronic HF Study). Late-Breaking and Recent Clinical Trials. Presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America; September 12–15, 2004, Toronto, Ontario, Canada. (Abstract).
51.
Holubarsch CJF, Colucci WS, Meinertz T, et al. Crataegus extract WS 1442 postpones cardiac death in patients with congestive heart failure class NYHA II–III: a randomized, placebo-controlled, double-blind trial in 2681 patients. American College of Cardiology 2007 Scientific Sessions March 27, 2007; New Orleans, LA. Late breaking clinical trials-3, Session 414–5. (Abstract)
Metadaten
Titel
Effects of Hawthorn on Cardiac Remodeling and Left Ventricular Dysfunction after 1 Month of Pressure Overload-induced Cardiac Hypertrophy in Rats
verfasst von
Hyun Seok Hwang
Barry E. Bleske
Michael M. J. Ghannam
Kimber Converso
Mark W. Russell
James C. Hunter
Marvin O. Boluyt
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2008
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-008-6082-2

Weitere Artikel der Ausgabe 1/2008

Cardiovascular Drugs and Therapy 1/2008 Zur Ausgabe

OriginalPaper

Use of Anticoagulants in ST-Segment Elevation Myocardial Infarction Patients; A Focus on Low-Molecular-Weight Heparin

OriginalPaper

Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in Pigs

Letter to the Editor

Renin Inhibitors in Cardiovascular Surgery

ReviewPaper

Management of Tako-tsubo Syndrome

OriginalPaper

CREB Activation and Ischaemic Preconditioning

OriginalPaper

Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise